Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
Financial Results:
Aurobindo Pharma Ltd reported Revenues for Q4FY25 of ₹8,382.00 Crores up from ₹7,580.00 Crore year on year, a rise of 10.58%.
Total Expenses for Q4FY25 of ₹7,181.00 Crores up from ₹6,363.00 Crores year on year, a rise of 12.86%.
Consolidated Net Profit of ₹903.00 Crores down 0.44% from ₹907.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹15.42, down 0.58% from ₹15.51 in the same quarter of the previous year.